SCHEMBL578136

SCHEMBL578136

Cc1n[nH]cc1B(O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL13279832 0.98 LMNA (0.31)
SCHEMBL19682753 0.86
Boric Acid SCHEMBL28360746 0.75
Boric Acid SCHEMBL31079547 0.75
SCHEMBL245719 0.73
SCHEMBL28688664 0.70
SCHEMBL22091090 0.70
SCHEMBL18603247 0.70
SCHEMBL2634822 0.69 MEN1 (0.43)
SCHEMBL2762229 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719382-A1 INHIBITORS OF TYPE 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM University of Washington (US) 2026-04-08 EP disclosed
US-20260049074-A1 THIADIAZOLYL DERIVATIVES IDEAYA BIOSCIENCES, INC. (US) 2026-02-19 US disclosed
US-12516059-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2026-01-06 US disclosed
US-12509454-B2 Thiadiazolyl derivatives IDEAYA BIOSCIENCES, INC. (US) 2025-12-30 US disclosed
US-12454529-B2 Piperazine cyclic ureas Sironax Ltd. (KY) 2025-10-28 US disclosed
EP-4573094-A2 CDK2 INHIBITORS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-06-25 EP disclosed
EP-4572755-A2 CDK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-06-25 EP disclosed
CN-119912402-A FTO inhibitor and preparation method and application thereof 中国科学院上海药物研究所 2025-05-02 CN disclosed
US-12258323-B2 Dihydrooxadiazinones BAYER AKTIENGESELLSCHAFT (DE) 2025-03-25 US disclosed
EP-4476204-A1 COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS Theras, Inc. (US) 2024-12-18 EP disclosed
EP-1382603-B1 NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF EISAI R&D MAN CO LTD (JP) 2008-07-23 EP disclosed
US-20070270603-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-11-22 US disclosed
US-7271280-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-18 US disclosed
US-7091373-B2 Production method for biarylalanine SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-08-15 US disclosed
US-7074801-B1 Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof EISAI CO., LTD. (JP) 2006-07-11 US disclosed
EP-1481967-A1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS Sumitomo Chemical Company, Limited (JP) 2004-12-01 EP disclosed
US-20040158093-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-12 US disclosed
US-20040024229-A1 Production method for biarylalanine SUMITOMO CHEMICAL COMPANY, LIMITED 2004-02-05 US disclosed
EP-1382603-A1 NITROGENOUS FUSED&amp;minus;RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF Eisai Co., Ltd. (JP) 2004-01-21 EP disclosed
EP-1346971-A1 Production method for biarylalanine SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-09-24 EP disclosed